Jean-Francois Korobelnik

Participates in 2 items

Sessions in which Jean-Francois Korobelnik participates

viernes 20 junio, 2025

Zona horaria: (GMT-05:00) Eastern Time (US & Canada)

A 96-week PULSAR Phase 3 trial post-hoc analysis: Rapid and sustained fluid control with aflibercept 8mg every 12 weeks or longer, as defined by fluid-free status at Weeks 16, 48, and 96 stratified by baseline CRT and BCVA - 5434

12:11 - 12:16 | 5 minutos

Vancouver Convention Centre (East Building) - Ballroom B

Jean-Francois Korobelnik (Speaker)

12:16 - 12:19 | 3 minutos

Vancouver Convention Centre (East Building) - Ballroom B